Pretax income is the income that a company earns before paying income taxes. Lexeo Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-21.68 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-69.42 Mil.
Lexeo Therapeutics's pretax margin was %.
During the past 4 years, Lexeo Therapeutics's highest Pretax Margin was -994.79%. The lowest was -9063.76%. And the median was -3055.04%.
Lexeo Therapeutics Pre-Tax Income Historical Data
The historical data trend for Lexeo Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexeo Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Lexeo Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's Pre-Tax Income falls into.
Lexeo Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Lexeo Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics (NAS:LXEO) Pre-Tax Income Explanation
Lexeo Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 4 years, Lexeo Therapeutics's highest Pretax Margin was -994.79%. The lowest was -9063.76%. And the median was -3055.04%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Lexeo Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexeo Therapeutics (Lexeo Therapeutics) Business Description
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LXEO has been successfully added to your 